… 8-10 paragraphs, 1400-1600 words total. Need to write a long article. Let me plan ~9 paragraphs of ~160-175 words each = ~1500 words. Content based on abstract: particle engineering, SCF processes limited by large high-pressure vessels, scCO2-assisted spray technologies (SAA, SEA, SASD), mechanisms, applications (dissolution enhancement, polymorph control, inhalable dry powders, controlled release, thermolabile biologics, natural bioactives), limitations, path to commercialization (continuous manufacturing, QbD, CFD), expert opinion that strength is single-step co-processing under mild conditions, SASD most practical due to retrofit compatibility. Can cite specific examples from references: salmon calcitonin, lysozyme, insulin, fenofibrate, cocrystals (indomethacin-saccharin), carbamazepine polymorphism, liposomal dry powders, quercetin{

The appeal of supercritical carbon dioxide as a processing medium stems from its accessible critical point, with a critical temperature of approximately 31 degrees Celsius and a critical pressure of roughly 74 bar. Above these thresholds, carbon dioxide behaves as a hybrid of gas and liquid, diffusing like a gas while dissolving solutes like a liquid, yet leaving no toxic residue when it depressurizes. For pharmaceutical manufacturing, this combination is unusually forgiving: solvents can be stripped from products at temperatures low enough to spare delicate molecules, and the gas can be recycled or simply vented, leaving nothing behind that a regulator would classify as a residual solvent. These attributes explain why carbon dioxide dominates the supercritical fluid literature in pharmacy, even as other fluids such as propane, ethane, and water have been explored for niche applications where their particular solvent properties are advantageous.

The classical supercritical antisolvent process, which has accumulated the deepest body of pharmaceutical evidence, works by dissolving carbon dioxide into an organic drug solution before the solvent is extracted, precipitating solute particles from a supersaturated mixture. Its limitation is structural rather than chemical: precipitation occurs inside a pressurized vessel whose volume must be large enough to accommodate production batches, and the vessel walls constrain both throughput and the uniformity of conditions across the precipitation zone. The spray-based variants reviewed here invert this logic. Instead of relying on bulk precipitation within a chamber, they use dissolved or compressed carbon dioxide to shatter a liquid feed into fine droplets at a nozzle, so that particle formation happens droplet by droplet in flight. The pressure vessel then serves mainly as a collection and drying space rather than as the reactor itself, which relaxes the volume requirements that have historically hampered industrial adoption.

Understanding how carbon dioxide assists atomization clarifies why the resulting particles differ from those of conventional spray drying. When pressurized carbon dioxide mixes with an aqueous or organic feed at a nozzle, dissolved gas nucleates explosively as pressure falls, and the expanding bubbles tear the liquid sheet apart into droplets far smaller than mechanical nozzles alone would produce. The intense gas expansion also promotes rapid evaporation of the primary solvent, shortening the time available for solute migration within the drying droplet. This matters for solid-state control: if solvent removal outpaces diffusion, individual drug molecules or amorphous domains are frozen in place, favoring amorphous solids or metastable polymorphs; if drying is slower, crystals with more equilibrium character can grow. Process variables such as carbon dioxide-to-solvent ratio, feed concentration, nozzle geometry, and drying temperature therefore act as levers for tuning particle size, morphology, and crystallinity, and their systematic mapping is a recurring theme across the reviewed studies.

The distinction between supercritical-assisted atomization, supercritical enhanced atomization, and supercritical carbon dioxide-assisted spray drying lies mainly in where the carbon dioxide is introduced and how much of the drying it accomplishes. In supercritical-assisted atomization, carbon dioxide is dissolved into the liquid feed in a saturator before expansion, and a heated gas stream completes solvent evaporation downstream. Enhanced atomization variants inject the pressurized gas directly at a two-fluid nozzle, exploiting its kinetic energy to complement or replace conventional atomizing air. The spray-drying variant goes furthest, feeding carbon dioxide-assisted atomized droplets into a modified spray dryer where conventional drying equipment finishes the job. Because the last configuration preserves the familiar architecture of an industrial spray dryer, it can often be implemented by retrofitting existing lines rather than building dedicated high-pressure plants, a practical consideration that weighs heavily in the technology’s commercial prospects.

Evidence for dissolution enhancement spans a striking range of drug classes and delivery challenges. Poorly water-soluble molecules, which dominate modern discovery pipelines, benefit from the micron and submicron particle sizes these processes deliver, since dissolution rate scales inversely with particle dimensions. Co-processing with hydrophilic carriers such as polyvinylpyrrolidone produces amorphous solid dispersions in a single step, avoiding the solvent-intensive and thermally stressful unit operations of conventional dispersion manufacturing. Published work on cannabidiol loaded into polyvinylpyrrolidone microparticles illustrates the approach for a highly lipophilic active whose oral absorption is notoriously erratic, while earlier studies on anti-inflammatory and antifungal compounds established the general principle that spray-formed composites can outperform physically mixed equivalents in both rate and extent of dissolution.

Control over polymorphism and cocrystal formation represents a quieter but strategically important application. The solid form of a drug determines its solubility, stability, manufacturability, and intellectual property position, yet conventional crystallization often delivers only the forms accessible from solution thermodynamics. Spray-based supercritical processing can trap metastable polymorphs or generate cocrystals with stoichiometries difficult to reach in bulk solution, because the rapid drying of atomized droplets bypasses the slow equilibration that normally steers crystallization toward the thermodynamic product. Studies of model compounds have demonstrated that adjusting the carbon dioxide pressure and drying temperature selects among anhydrous forms, hydrates, and amorphous phases, giving formulators a degree of solid-state control that complements rather than replaces classical screening methods.

Inhalable dry powders have emerged as perhaps the most demanding test of these technologies, and the results are instructive. Respiratory formulations require particles in a narrow aerodynamic diameter range, typically between one and five micrometers, with low cohesiveness and controlled flow. Conventional jet milling damages crystals and generates broad distributions, while spray drying from organic solvents raises residue and safety questions. Supercritical carbon dioxide-assisted spray drying produces respirable fractions with gentler thermal exposure and cleaner solvent profiles, and published work on salmon calcitonin for nasal delivery demonstrated that the process preserved peptide integrity while achieving particle sizes suited to mucosal absorption. Combination with excipients such as amino acids and sugars, which act as dispersibility enhancers and stabilizers, integrates naturally into the single-step format.

The extension to biologics and thermolabile actives is where the mild-conditions argument becomes decisive. Proteins, vaccines, and liposomal formulations are degraded by the organic solvents, high shear, and elevated temperatures of conventional microparticle production. Because supercritical carbon dioxide is inert toward most biomolecules and operates near ambient temperature, it has been used to dry enzymes, antibodies, and liposome suspensions into inhalable powders without measurable loss of activity. Recent proof-of-concept studies on liposomal dry powders carrying superoxide dismutase, an antioxidant enzyme, showed that the lipid bilayers survived atomization and drying intact, and that the resulting powders retained aerosol performance. Similar logic applies to natural bioactives extracted from food and agricultural waste streams, such as polyphenols and carotenoids, which are notoriously unstable in conventional processing but can be encapsulated in biopolymer matrices formed during spray drying.

Controlled release applications exploit a different facet of the technology: the ability to co-precipitate drug and polymer in defined ratios within each droplet. Microparticles for wound treatment, exemplified by gentamicin loaded in dextran matrices, demonstrated sustained local antibiotic release while maintaining the aminoglycoside’s activity through a solvent-free process. Albumin microspheres carrying antibiotics have likewise been produced with loading levels and release kinetics that depend predictably on feed composition and process conditions. Because the drug and carrier solidify simultaneously from the same droplet, the method avoids the segregation and heterogeneity that plague post-hoc coating approaches, and the absence of organic solvent residues simplifies regulatory pathways for parenteral and implantable formats.

The path from laboratory demonstration to commercial manufacturing runs through several bottlenecks that the review identifies candidly. Scale-up of atomization is not trivial: nozzle hydrodynamics change with diameter, and the near-field mixing of pressurized carbon dioxide with liquid feed is governed by multiphase flow physics that only recently has become amenable to computational fluid dynamics simulation. Recent modeling work characterizing pressurized carbon dioxide flow through micro-orifices and two-fluid nozzles provides the quantitative foundation needed to predict droplet sizes at production scale rather than relying on empirical correlation. Alongside modeling, quality-by-design frameworks require systematic mapping of critical process parameters to critical quality attributes, and design-of-experiments studies published over the past decade show that this mapping is feasible even for the complex phase behavior of carbon dioxide-solvent-drug mixtures.

Continuous manufacturing compatibility is the remaining piece of the industrial puzzle. Pharmaceutical regulators increasingly favor continuous processes for their consistent quality and reduced inventory, and spray-based particle formation is inherently continuous in its core operation, with liquid feed, pressurized gas, and drying gas flowing steadily through the equipment. The challenge lies in the peripheral steps: feed preparation, sterile processing for injectable or inhalable products, and in-line analytical verification of particle attributes. Sterile continuous processing of biologics by supercritical spray methods remains largely unproven at manufacturing scale, and validated cleaning procedures for high-pressure equipment present their own engineering questions. Progress on these fronts, combined with standardized benchmarking against conventional spray drying across multiple platforms, will determine whether the technology graduates from specialized applications to mainstream pharmaceutical production.

The overall assessment that emerges is measured but optimistic. These technologies will not displace conventional spray drying where the latter performs adequately, and their economics favor applications where mild conditions, solvent-free products, or single-step co-processing confer genuine advantage. Thermolabile biologics, inhalable formulations of sensitive molecules, and natural bioactives are the natural strongholds. For manufacturers weighing investment, the retrofit pathway offered by the spray-drying variant lowers the barrier considerably, allowing existing assets to be adapted rather than replaced. What the field needs now is not more proof-of-concept papers but disciplined scale-up studies, regulatory engagement, and head-to-head comparisons that quantify the benefits in terms regulators and payers recognize.

Subject of Research: Recent advances in supercritical CO2-assisted spray particle formation technologies

Article Title: Recent advances in supercritical CO2-assisted spray particle formation technologies

Article References: Kim, J.-S., Ha, E.-S., Kim, M.-S., Park, H., & Hwang, S.-J. (2026). Recent advances in supercritical CO2-assisted spray particle formation technologies. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-026-00836-z

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00836-z

Keywords: Recent, advances, supercritical, CO2-assisted, spray, particle, formation, technologies, scientific research